X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Vazkepa (icosapent ethyl) is an ethyl ester of eicosapentaenoic acid that reduces synthesis and enhances clearance of triglycerides that is used to treat patients with severe hypertriglyceridemia.
Lead Product(s): Icosapent Ethyl
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vazkepa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
Under the agreement, Amarin has appointed Neopharm as its sole and exclusive distributor of Vazkepa (icosapent ethyl) approved to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides in Israel.
Lead Product(s): Icosapent Ethyl
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vazkepa
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Neopharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 08, 2023
Details:
The partnership aims to distribute and commercialize Vazkepa (icosapent ethyl), approved and commercialized in a number of global markets, including the U.S. and European markets, across 10 countries, including nine in Southeast Asia and South Korea.
Lead Product(s): Icosapent Ethyl
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vazkepa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lotus Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 31, 2023
Details:
VASCEPA/VAZKEPA (icosapent ethyl) Capsules first prescription treatment approved by the FDA comprised solely of the active ingredient, icosapent ethyl, a unique form of eicosapentaenoic acid for the treatment of Hypertriglyceridemia and Reduce Cardiovascular Risk.
Lead Product(s): Icosapent Ethyl
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vascepa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
VASCEPA®/VAZKEPA® (icosapent ethyl) Capsules first prescription treatment approved by the FDA comprised solely of the active ingredient, icosapent ethyl, a unique form of eicosapentaenoic acid for the treatment of adult patients with severe Hypertriglyceridemia.
Lead Product(s): Icosapent Ethyl
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vascepa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Edding Pharm
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
Vazkepa (icosapent ethyl) is a medicine for reducing the risk of cardiovascular events such as heart attack, stroke and other problems caused by blocked blood circulation
Lead Product(s): Icosapent Ethyl
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vazkepa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
Vazkepa (icosapent ethyl) is an ethyl ester of eicosapentaenoic acid that reduces synthesis and enhances clearance of triglycerides that is used to treat patients with severe hypertriglyceridemia.
Lead Product(s): Icosapent Ethyl
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undislclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
Under the terms of the agreement, Amarin will license exclusive rights to Vazkepa (icosapent ethyl) to CSL Seqirus to secure pricing and reimbursement and commercialize the product across Australia and New Zealand.
Lead Product(s): Icosapent Ethyl
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vazkepa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Seqirus
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 28, 2023
Details:
Vazkepa (icosapent ethyl) is an ethyl ester of eicosapentaenoic acid that reduces synthesis and enhances clearance of triglycerides that is used to treat patients with severe hypertriglyceridemia.
Lead Product(s): Icosapent Ethyl
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vazkepa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2023
Details:
VASCEPA/VAZKEPA (icosapent ethyl) capsules are the first prescription treatment comprised solely of the active ingredient, icosapent ethyl, a highly purified form of eicosapentaenoic acid.
Lead Product(s): Icosapent Ethyl
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vazkepa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
